CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Tiziana doses first three patients in ALS trial of nasal antibody foralumab

Trial StartforalumabPositive
AI Analysis

Summary

Tiziana has dosed the first three patients in an ALS trial of its nasal antibody foralumab, marking the initiation of patient enrollment in this clinical program.

Clinical Trial Data

Patients

3

Importance:4/10
Sentiment:
0.30
ALSnasal antibodyclinical trialpatient dosing
Related Companies

Read the original article

Published by yahoo_finance on September 28, 2026 1:14 PM

Read Original